Evidence map›Paper›PMID 26466672›Full record

ArticleRadiation oncology (London, England)2015

Feasibility of accelerated partial breast irradiation with volumetric-modulated arc therapy in elderly and frail patients.

Olivier Riou, Pascal Fenoglietto, Céline Bourgier, Olivier Lauche, Fatiha Boulbair, Marie Charissoux, Angélique Ducteil, Norbert Aillères, Claire Lemanski, David Azria

Open access · goldAbstract read
In one paragraph

Article in Radiation oncology (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Olivier RiouRadiation Oncology Department, Institut régional du Cancer de Montpellier (ICM), Val d'Aurelle, 208 avenue des Apothicaires, 34298, Montpellier, cedex 5, France. riouo@hotmail.com.
Pascal FenogliettoRadiation Oncology Department, Institut régional du Cancer de Montpellier (ICM), Val d'Aurelle, 208 avenue des Apothicaires, 34298, Montpellier, cedex 5, France. pascal.fenoglietto@icm.unicancer.fr.
Céline BourgierRadiation Oncology Department, Institut régional du Cancer de Montpellier (ICM), Val d'Aurelle, 208 avenue des Apothicaires, 34298, Montpellier, cedex 5, France. celine.bourgier@icm.unicancer.fr.
Olivier LaucheRadiation Oncology Department, Institut régional du Cancer de Montpellier (ICM), Val d'Aurelle, 208 avenue des Apothicaires, 34298, Montpellier, cedex 5, France. Olivier.lauche@icm.unicancer.fr.
Fatiha BoulbairRadiotherapy Department, Mulhouse Hospital, Mulhouse, France. boulbairf@ch-mulhouse.fr.
Marie CharissouxRadiation Oncology Department, Institut régional du Cancer de Montpellier (ICM), Val d'Aurelle, 208 avenue des Apothicaires, 34298, Montpellier, cedex 5, France. Marie.charissoux@icm.unicancer.fr.
Angélique DucteilRadiation Oncology Department, Institut régional du Cancer de Montpellier (ICM), Val d'Aurelle, 208 avenue des Apothicaires, 34298, Montpellier, cedex 5, France. Angelique.ducteil@icm.unicancer.fr.
Norbert AillèresRadiation Oncology Department, Institut régional du Cancer de Montpellier (ICM), Val d'Aurelle, 208 avenue des Apothicaires, 34298, Montpellier, cedex 5, France. Norbert.ailleres@icm.unicancer.fr.
Claire LemanskiRadiation Oncology Department, Institut régional du Cancer de Montpellier (ICM), Val d'Aurelle, 208 avenue des Apothicaires, 34298, Montpellier, cedex 5, France. Claire.lemanski@icm.unicancer.fr.
David AzriaRadiation Oncology Department, Institut régional du Cancer de Montpellier (ICM), Val d'Aurelle, 208 avenue des Apothicaires, 34298, Montpellier, cedex 5, France. David.azria@icm.unicancer.fr.
Institut de Recherche en Cancérologie de Montpellier · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccelerated partial breast irradiation (APBI) is an option for adjuvant radiotherapy according to ASTRO and ESTRO recommendations. Among the available techniques, volumetric-modulated arc therapy (VMAT) is attractive but has not been extensively studied for APBI. This study assessed its feasibility, tolerance and early oncological outcomes.

methodsWe analysed the data of nine patients (median age 74 years) with ten lesions (one bilateral cancer) treated from May 2011 to July 2012 with APBI using VMAT. The radiation oncologist delineated the surgical tumour bed, and added an 18 mm isotropic margin to obtain the planning target volume (PTV). The dose was 40 Gy prescribed in 4 Gy fractions given twice a day over five days. Patients were regularly followed for toxicities and oncological outcomes.

resultsMean PTV was 100.0 cm(3) and 95 % of the PTV received a mean dose of 99.7 % of the prescribed dose. Hot spots represented 0.3 % of the PTV. 6.2 %, 1.6 % and 0.3 % of the ipsilateral lung volume received 5 Gy (V5Gy), 10 Gy (V10Gy) and 20 Gy (V20Gy), respectively. Regarding the contralateral lung, V5Gy was 0.3 %, and V10Gy and V20Gy were nil. V5Gy accounted for 3.1 % of the heart. An average 580 monitor units were delivered. No acute or late grade ≥ 2 toxicities were observed. With a median follow-up of 26 months, no relapses occurred.

conclusionIn our study, VMAT allowed optimal dosimetry with consequential high therapeutic ratio in elderly and frail patients.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsFemaleFrail ElderlyHumansOrgans at RiskRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-Assisted

Identifiers

PMID26466672
PMCPMC4606890
OpenAlexW1956200899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.